DK2814514T3 - Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases - Google Patents

Info

Publication number

DK2814514T3

DK2814514T3 DK13749967.9T DK13749967T DK2814514T3 DK 2814514 T3 DK2814514 T3 DK 2814514T3 DK 13749967 T DK13749967 T DK 13749967T DK 2814514 T3 DK2814514 T3 DK 2814514T3

Authority

DK

Denmark

Prior art keywords

hrs

present disclosure

hrs polypeptide

polypeptide

disease

Prior art date

2012-02-16

Links

• Espacenet
• Global Dossier
• Discuss

• 102000029746 Histidine-tRNA Ligase Human genes 0.000 title claims description 147
• 101710177011 Histidine-tRNA ligase, cytoplasmic Proteins 0.000 title claims description 146
• 101710096715 Probable histidine-tRNA ligase, cytoplasmic Proteins 0.000 title claims description 146
• 238000011282 treatment Methods 0.000 title claims description 50
• 208000023275 Autoimmune disease Diseases 0.000 title claims description 40
• 208000027866 inflammatory disease Diseases 0.000 title claims description 21
• 230000001363 autoimmune Effects 0.000 title claims description 15
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 450
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 441
• 229920001184 polypeptide Polymers 0.000 claims description 437
• 239000000203 mixture Substances 0.000 claims description 168
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 142
• 201000010099 disease Diseases 0.000 claims description 118
• 238000000034 method Methods 0.000 claims description 114
• 235000001014 amino acid Nutrition 0.000 claims description 86
• 150000001413 amino acids Chemical class 0.000 claims description 85
• 201000002481 Myositis Diseases 0.000 claims description 57
• 230000001225 therapeutic effect Effects 0.000 claims description 57
• 230000001965 increasing effect Effects 0.000 claims description 43
• 201000001981 dermatomyositis Diseases 0.000 claims description 32
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 31
• 208000005987 polymyositis Diseases 0.000 claims description 30
• 230000002829 reductive effect Effects 0.000 claims description 29
• 208000029523 Interstitial Lung disease Diseases 0.000 claims description 28
• 239000002158 endotoxin Substances 0.000 claims description 26
• 201000006938 muscular dystrophy Diseases 0.000 claims description 24
• 210000001124 body fluid Anatomy 0.000 claims description 22
• 239000010839 body fluid Substances 0.000 claims description 22
• 208000035475 disorder Diseases 0.000 claims description 22
• 201000008319 inclusion body myositis Diseases 0.000 claims description 19
• 206010006895 Cachexia Diseases 0.000 claims description 17
• 206010003246 arthritis Diseases 0.000 claims description 17
• 239000007787 solid Substances 0.000 claims description 17
• 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 13
• 206010068871 Myotonic dystrophy Diseases 0.000 claims description 13
• 206010039020 Rhabdomyolysis Diseases 0.000 claims description 13
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 13
• 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 13
• 230000035772 mutation Effects 0.000 claims description 13
• 206010039710 Scleroderma Diseases 0.000 claims description 11
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 11
• 102100034239 Emerin Human genes 0.000 claims description 10
• 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 claims description 10
• 206010028289 Muscle atrophy Diseases 0.000 claims description 10
• 208000029549 Muscle injury Diseases 0.000 claims description 10
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
• 201000000585 muscular atrophy Diseases 0.000 claims description 9
• 229920000642 polymer Polymers 0.000 claims description 8
• 230000015572 biosynthetic process Effects 0.000 claims description 6
• 208000001839 Antisynthetase syndrome Diseases 0.000 claims description 5
• 229920002472 Starch Polymers 0.000 claims description 5
• 230000004071 biological effect Effects 0.000 claims description 5
• 235000019698 starch Nutrition 0.000 claims description 5
• 239000004952 Polyamide Substances 0.000 claims description 4
• 229920000669 heparin Polymers 0.000 claims description 4
• 229960002897 heparin Drugs 0.000 claims description 4
• 229920002647 polyamide Polymers 0.000 claims description 4
• 239000000377 silicon dioxide Substances 0.000 claims description 4
• 229920000936 Agarose Polymers 0.000 claims description 3
• 239000011324 bead Substances 0.000 claims description 3
• 229920002678 cellulose Polymers 0.000 claims description 3
• 235000010980 cellulose Nutrition 0.000 claims description 3
• 239000011521 glass Substances 0.000 claims description 3
• 150000004676 glycans Chemical class 0.000 claims description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
• 229920001282 polysaccharide Polymers 0.000 claims description 3
• 239000005017 polysaccharide Substances 0.000 claims description 3
• 238000002360 preparation method Methods 0.000 claims description 3
• 229920001059 synthetic polymer Polymers 0.000 claims description 3
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
• 244000215068 Acacia senegal Species 0.000 claims description 2
• 229920001817 Agar Polymers 0.000 claims description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
• 229920001661 Chitosan Polymers 0.000 claims description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
• 229920002907 Guar gum Polymers 0.000 claims description 2
• 229920000084 Gum arabic Polymers 0.000 claims description 2
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
• 229920000161 Locust bean gum Polymers 0.000 claims description 2
• 102000015728 Mucins Human genes 0.000 claims description 2
• 108010063954 Mucins Proteins 0.000 claims description 2
• 239000004642 Polyimide Substances 0.000 claims description 2
• 239000004793 Polystyrene Chemical class 0.000 claims description 2
• 229920001615 Tragacanth Polymers 0.000 claims description 2
• 235000010489 acacia gum Nutrition 0.000 claims description 2
• 239000000205 acacia gum Substances 0.000 claims description 2
• 150000003926 acrylamides Chemical class 0.000 claims description 2
• 239000008272 agar Substances 0.000 claims description 2
• 229940023476 agar Drugs 0.000 claims description 2
• 235000010419 agar Nutrition 0.000 claims description 2
• 229940072056 alginate Drugs 0.000 claims description 2
• 235000010443 alginic acid Nutrition 0.000 claims description 2
• 229920000615 alginic acid Polymers 0.000 claims description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
• 235000010418 carrageenan Nutrition 0.000 claims description 2
• 229920001525 carrageenan Polymers 0.000 claims description 2
• 239000000679 carrageenan Substances 0.000 claims description 2
• 229940113118 carrageenan Drugs 0.000 claims description 2
• 235000010417 guar gum Nutrition 0.000 claims description 2
• 239000000665 guar gum Substances 0.000 claims description 2
• 229960002154 guar gum Drugs 0.000 claims description 2
• 235000019314 gum ghatti Nutrition 0.000 claims description 2
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
• 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 2
• 235000010420 locust bean gum Nutrition 0.000 claims description 2
• 239000000711 locust bean gum Substances 0.000 claims description 2
• FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical class CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 2
• 229940051875 mucins Drugs 0.000 claims description 2
• 229920005615 natural polymer Polymers 0.000 claims description 2
• 239000001814 pectin Substances 0.000 claims description 2
• 229920001277 pectin Polymers 0.000 claims description 2
• 235000010987 pectin Nutrition 0.000 claims description 2
• 229920000058 polyacrylate Polymers 0.000 claims description 2
• 229920000728 polyester Polymers 0.000 claims description 2
• 229920000570 polyether Polymers 0.000 claims description 2
• 229920001721 polyimide Polymers 0.000 claims description 2
• 229920000098 polyolefin Polymers 0.000 claims description 2
• 229920002223 polystyrene Chemical class 0.000 claims description 2
• 239000005373 porous glass Substances 0.000 claims description 2
• 229920005989 resin Polymers 0.000 claims description 2
• 239000011347 resin Substances 0.000 claims description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
• 229920001285 xanthan gum Polymers 0.000 claims description 2
• 235000010493 xanthan gum Nutrition 0.000 claims description 2
• 239000000230 xanthan gum Substances 0.000 claims description 2
• 229940082509 xanthan gum Drugs 0.000 claims description 2
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
• 239000000420 anogeissus latifolia wall. gum Substances 0.000 claims 1
• 239000000305 astragalus gummifer gum Substances 0.000 claims 1
• 229920000591 gum Polymers 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 95
• 229940024606 amino acid Drugs 0.000 description 86
• 230000004054 inflammatory process Effects 0.000 description 81
• 206010061218 Inflammation Diseases 0.000 description 76
• 108090000623 proteins and genes Proteins 0.000 description 66
• 230000000951 immunodiffusion Effects 0.000 description 63
• 210000003205 muscle Anatomy 0.000 description 57
• 150000007523 nucleic acids Chemical class 0.000 description 53
• 102000039446 nucleic acids Human genes 0.000 description 51
• 108020004707 nucleic acids Proteins 0.000 description 51
• 235000018102 proteins Nutrition 0.000 description 49
• 102000004169 proteins and genes Human genes 0.000 description 49
• 230000000694 effects Effects 0.000 description 48
• 208000024891 symptom Diseases 0.000 description 46
• 210000001519 tissue Anatomy 0.000 description 45
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 39
• 210000001744 T-lymphocyte Anatomy 0.000 description 33
• 239000003814 drug Substances 0.000 description 33
• 230000004968 inflammatory condition Effects 0.000 description 31
• 230000027455 binding Effects 0.000 description 30
• 239000000427 antigen Substances 0.000 description 29
• 230000014509 gene expression Effects 0.000 description 29
• 208000015181 infectious disease Diseases 0.000 description 28
• 230000002757 inflammatory effect Effects 0.000 description 28
• 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 27
• 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 27
• 108091007433 antigens Proteins 0.000 description 27
• 102000036639 antigens Human genes 0.000 description 27
• 229940079593 drug Drugs 0.000 description 26
• 208000006673 asthma Diseases 0.000 description 23
• 210000004369 blood Anatomy 0.000 description 23
• 239000008280 blood Substances 0.000 description 23
• 230000028709 inflammatory response Effects 0.000 description 23
• 208000014769 Usher Syndromes Diseases 0.000 description 22
• 206010006451 bronchitis Diseases 0.000 description 22
• 239000000872 buffer Substances 0.000 description 22
• 241000282414 Homo sapiens Species 0.000 description 20
• 208000037976 chronic inflammation Diseases 0.000 description 20
• 230000006020 chronic inflammation Effects 0.000 description 20
• 206010028980 Neoplasm Diseases 0.000 description 19
• 125000003275 alpha amino acid group Chemical group 0.000 description 19
• 210000004072 lung Anatomy 0.000 description 19
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 18
• -1 HRS Proteins 0.000 description 18
• 230000001684 chronic effect Effects 0.000 description 18
• 230000037430 deletion Effects 0.000 description 18
• 238000012217 deletion Methods 0.000 description 18
• 210000002966 serum Anatomy 0.000 description 17
• 102000004127 Cytokines Human genes 0.000 description 16
• 108090000695 Cytokines Proteins 0.000 description 16
• 208000010428 Muscle Weakness Diseases 0.000 description 16
• 206010028372 Muscular weakness Diseases 0.000 description 16
• 239000012634 fragment Substances 0.000 description 16
• 210000002865 immune cell Anatomy 0.000 description 16
• 230000004044 response Effects 0.000 description 16
• 230000000875 corresponding effect Effects 0.000 description 15
• 239000002773 nucleotide Substances 0.000 description 15
• 210000000056 organ Anatomy 0.000 description 15
• 238000002560 therapeutic procedure Methods 0.000 description 15
• 238000002965 ELISA Methods 0.000 description 14
• 206010020751 Hypersensitivity Diseases 0.000 description 14
• 230000028993 immune response Effects 0.000 description 14
• 238000004519 manufacturing process Methods 0.000 description 14
• 125000003729 nucleotide group Chemical group 0.000 description 14
• 239000000126 substance Substances 0.000 description 14
• 208000021642 Muscular disease Diseases 0.000 description 13
• 201000009623 Myopathy Diseases 0.000 description 13
• 241000700159 Rattus Species 0.000 description 13
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 13
• 230000006378 damage Effects 0.000 description 13
• 210000003491 skin Anatomy 0.000 description 13
• 230000014616 translation Effects 0.000 description 13
• 201000011510 cancer Diseases 0.000 description 12
• 230000001404 mediated effect Effects 0.000 description 12
• 230000000750 progressive effect Effects 0.000 description 12
• 208000011580 syndromic disease Diseases 0.000 description 12
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 12
• 206010011878 Deafness Diseases 0.000 description 11
• 201000004624 Dermatitis Diseases 0.000 description 11
• 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 11
• 108091028043 Nucleic acid sequence Proteins 0.000 description 11
• 201000002786 Perrault syndrome Diseases 0.000 description 11
• 238000002835 absorbance Methods 0.000 description 11
• 208000026935 allergic disease Diseases 0.000 description 11
• 230000001413 cellular effect Effects 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 210000002216 heart Anatomy 0.000 description 11
• 210000002381 plasma Anatomy 0.000 description 11
• 201000006935 Becker muscular dystrophy Diseases 0.000 description 10
• 102000014914 Carrier Proteins Human genes 0.000 description 10
• 208000027418 Wounds and injury Diseases 0.000 description 10
• 230000007815 allergy Effects 0.000 description 10
• 108091008324 binding proteins Proteins 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 208000016354 hearing loss disease Diseases 0.000 description 10
• 208000014674 injury Diseases 0.000 description 10
• 238000006467 substitution reaction Methods 0.000 description 10
• 241000894006 Bacteria Species 0.000 description 9
• 206010006458 Bronchitis chronic Diseases 0.000 description 9
• 102000004420 Creatine Kinase Human genes 0.000 description 9
• 108010042126 Creatine kinase Proteins 0.000 description 9
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 9
• 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 9
• 241001465754 Metazoa Species 0.000 description 9
• 208000038016 acute inflammation Diseases 0.000 description 9
• 230000006022 acute inflammation Effects 0.000 description 9
• 238000007792 addition Methods 0.000 description 9
• 125000000539 amino acid group Chemical group 0.000 description 9
• 208000007451 chronic bronchitis Diseases 0.000 description 9
• 230000002860 competitive effect Effects 0.000 description 9
• 201000006815 congenital muscular dystrophy Diseases 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000001976 improved effect Effects 0.000 description 9
• 210000004698 lymphocyte Anatomy 0.000 description 9
• 210000002540 macrophage Anatomy 0.000 description 9
• 238000002844 melting Methods 0.000 description 9
• 230000008018 melting Effects 0.000 description 9
• 230000009885 systemic effect Effects 0.000 description 9
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
• 101000843187 Homo sapiens Histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 8
• 102000003960 Ligases Human genes 0.000 description 8
• 108090000364 Ligases Proteins 0.000 description 8
• 201000009906 Meningitis Diseases 0.000 description 8
• 206010035664 Pneumonia Diseases 0.000 description 8
• 229920001213 Polysorbate 20 Polymers 0.000 description 8
• 230000006472 autoimmune response Effects 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 210000004204 blood vessel Anatomy 0.000 description 8
• 201000009267 bronchiectasis Diseases 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 239000012530 fluid Substances 0.000 description 8
• 231100000888 hearing loss Toxicity 0.000 description 8
• 230000010370 hearing loss Effects 0.000 description 8
• 229960002885 histidine Drugs 0.000 description 8
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 8
• 230000001939 inductive effect Effects 0.000 description 8
• 230000008595 infiltration Effects 0.000 description 8
• 238000001764 infiltration Methods 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
• 229940068977 polysorbate 20 Drugs 0.000 description 8
• 206010039073 rheumatoid arthritis Diseases 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 238000013518 transcription Methods 0.000 description 8
• 230000035897 transcription Effects 0.000 description 8
• 108020004414 DNA Proteins 0.000 description 7
• 231100000491 EC50 Toxicity 0.000 description 7
• 206010014561 Emphysema Diseases 0.000 description 7
• 206010016654 Fibrosis Diseases 0.000 description 7
• 101100016399 Homo sapiens HARS1 gene Proteins 0.000 description 7
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
• 208000019693 Lung disease Diseases 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• 208000000112 Myalgia Diseases 0.000 description 7
• 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 7
• 230000001154 acute effect Effects 0.000 description 7
• 210000000577 adipose tissue Anatomy 0.000 description 7
• 230000002411 adverse Effects 0.000 description 7
• 206010009887 colitis Diseases 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 230000007547 defect Effects 0.000 description 7
• 201000009338 distal myopathy Diseases 0.000 description 7
• 230000004438 eyesight Effects 0.000 description 7
• 230000004761 fibrosis Effects 0.000 description 7
• 210000000987 immune system Anatomy 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 229920006008 lipopolysaccharide Polymers 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 210000000653 nervous system Anatomy 0.000 description 7
• 210000000440 neutrophil Anatomy 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 238000001243 protein synthesis Methods 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 230000008961 swelling Effects 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
• 208000011231 Crohn disease Diseases 0.000 description 6
• 206010061818 Disease progression Diseases 0.000 description 6
• 208000000059 Dyspnea Diseases 0.000 description 6
• 206010013975 Dyspnoeas Diseases 0.000 description 6
• 108010069091 Dystrophin Proteins 0.000 description 6
• 102000001039 Dystrophin Human genes 0.000 description 6
• 208000010201 Exanthema Diseases 0.000 description 6
• 208000002193 Pain Diseases 0.000 description 6
• 201000004681 Psoriasis Diseases 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 230000006229 amino acid addition Effects 0.000 description 6
• 239000003963 antioxidant agent Substances 0.000 description 6
• 235000006708 antioxidants Nutrition 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 210000003719 b-lymphocyte Anatomy 0.000 description 6
• 230000000903 blocking effect Effects 0.000 description 6
• 230000012085 chronic inflammatory response Effects 0.000 description 6
• 230000015271 coagulation Effects 0.000 description 6
• 238000005345 coagulation Methods 0.000 description 6
• 206010052015 cytokine release syndrome Diseases 0.000 description 6
• 230000005750 disease progression Effects 0.000 description 6
• 201000005884 exanthem Diseases 0.000 description 6
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
• 235000014304 histidine Nutrition 0.000 description 6
• 239000012678 infectious agent Substances 0.000 description 6
• 230000002458 infectious effect Effects 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 210000002414 leg Anatomy 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• 238000002483 medication Methods 0.000 description 6
• 238000013508 migration Methods 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 230000002685 pulmonary effect Effects 0.000 description 6
• 206010037844 rash Diseases 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 230000028327 secretion Effects 0.000 description 6
• 210000002027 skeletal muscle Anatomy 0.000 description 6
• 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 description 5
• 208000035143 Bacterial infection Diseases 0.000 description 5
• 206010011224 Cough Diseases 0.000 description 5
• 206010050685 Cytokine storm Diseases 0.000 description 5
• 208000037150 Dysferlin-related limb-girdle muscular dystrophy R2 Diseases 0.000 description 5
• 206010019280 Heart failures Diseases 0.000 description 5
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 5
• 206010040047 Sepsis Diseases 0.000 description 5
• 206010052779 Transplant rejections Diseases 0.000 description 5
• 102100040247 Tumor necrosis factor Human genes 0.000 description 5
• 206010052428 Wound Diseases 0.000 description 5
• 230000010398 acute inflammatory response Effects 0.000 description 5
• 230000002776 aggregation Effects 0.000 description 5
• 238000004220 aggregation Methods 0.000 description 5
• 208000007502 anemia Diseases 0.000 description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
• 201000009563 autosomal recessive limb-girdle muscular dystrophy type 2B Diseases 0.000 description 5
• 208000022362 bacterial infectious disease Diseases 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 239000011230 binding agent Substances 0.000 description 5
• 238000004422 calculation algorithm Methods 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 208000006111 contracture Diseases 0.000 description 5
• 239000003246 corticosteroid Substances 0.000 description 5
• 229960001334 corticosteroids Drugs 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 230000006872 improvement Effects 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 238000003780 insertion Methods 0.000 description 5
• 230000037431 insertion Effects 0.000 description 5
• 230000033001 locomotion Effects 0.000 description 5
• 206010025135 lupus erythematosus Diseases 0.000 description 5
• 230000005012 migration Effects 0.000 description 5
• 210000001616 monocyte Anatomy 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 229910052760 oxygen Inorganic materials 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 230000000770 proinflammatory effect Effects 0.000 description 5
• 230000001681 protective effect Effects 0.000 description 5
• 238000009256 replacement therapy Methods 0.000 description 5
• 208000013220 shortness of breath Diseases 0.000 description 5
• 238000001179 sorption measurement Methods 0.000 description 5
• 230000009870 specific binding Effects 0.000 description 5
• 230000002269 spontaneous effect Effects 0.000 description 5
• 230000009747 swallowing Effects 0.000 description 5
• 210000002435 tendon Anatomy 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 238000012085 transcriptional profiling Methods 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 208000004434 Calcinosis Diseases 0.000 description 4
• 206010007559 Cardiac failure congestive Diseases 0.000 description 4
• 108010077544 Chromatin Proteins 0.000 description 4
• 206010009900 Colitis ulcerative Diseases 0.000 description 4
• 241000701022 Cytomegalovirus Species 0.000 description 4
• 108090000620 Dysferlin Proteins 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 206010064147 Gastrointestinal inflammation Diseases 0.000 description 4
• 101000879354 Homo sapiens Alanine-tRNA ligase, cytoplasmic Proteins 0.000 description 4
• 101000696493 Homo sapiens Histidine-tRNA ligase, mitochondrial Proteins 0.000 description 4
• 206010068786 Overlap syndrome Diseases 0.000 description 4
• 206010033645 Pancreatitis Diseases 0.000 description 4
• 208000001647 Renal Insufficiency Diseases 0.000 description 4
• 229920002684 Sepharose Polymers 0.000 description 4
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 4
• 208000006011 Stroke Diseases 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 108020004566 Transfer RNA Proteins 0.000 description 4
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
• 208000025865 Ulcer Diseases 0.000 description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 description 4
• 206010047115 Vasculitis Diseases 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 208000010668 atopic eczema Diseases 0.000 description 4
• 230000005784 autoimmunity Effects 0.000 description 4
• 239000002981 blocking agent Substances 0.000 description 4
• 244000309466 calf Species 0.000 description 4
• 239000001569 carbon dioxide Substances 0.000 description 4
• 229910002092 carbon dioxide Inorganic materials 0.000 description 4
• 210000003483 chromatin Anatomy 0.000 description 4
• 239000007979 citrate buffer Substances 0.000 description 4
• 230000001086 cytosolic effect Effects 0.000 description 4
• 230000007850 degeneration Effects 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 239000000428 dust Substances 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 206010014599 encephalitis Diseases 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 210000000245 forearm Anatomy 0.000 description 4
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
• 230000009610 hypersensitivity Effects 0.000 description 4
• 230000002779 inactivation Effects 0.000 description 4
• 230000004941 influx Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 201000010659 intrinsic asthma Diseases 0.000 description 4
• 210000001503 joint Anatomy 0.000 description 4
• 201000006370 kidney failure Diseases 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 210000003041 ligament Anatomy 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 239000000693 micelle Substances 0.000 description 4
• 230000003387 muscular Effects 0.000 description 4
• 208000010125 myocardial infarction Diseases 0.000 description 4
• 210000001087 myotubule Anatomy 0.000 description 4
• 230000000926 neurological effect Effects 0.000 description 4
• 230000002611 ovarian Effects 0.000 description 4
• 239000000816 peptidomimetic Chemical class 0.000 description 4
• 210000002307 prostate Anatomy 0.000 description 4
• 238000011552 rat model Methods 0.000 description 4
• 230000000241 respiratory effect Effects 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 230000002459 sustained effect Effects 0.000 description 4
• 210000001541 thymus gland Anatomy 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• 201000008827 tuberculosis Diseases 0.000 description 4
• 210000002700 urine Anatomy 0.000 description 4
• 210000003462 vein Anatomy 0.000 description 4
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 3
• 208000023328 Basedow disease Diseases 0.000 description 3
• 102100033849 CCHC-type zinc finger nucleic acid binding protein Human genes 0.000 description 3
• 150000008574 D-amino acids Chemical class 0.000 description 3
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• 102000004168 Dysferlin Human genes 0.000 description 3
• 238000012286 ELISA Assay Methods 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 206010015150 Erythema Diseases 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 208000001640 Fibromyalgia Diseases 0.000 description 3
• 208000007882 Gastritis Diseases 0.000 description 3
• 206010018364 Glomerulonephritis Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 208000024869 Goodpasture syndrome Diseases 0.000 description 3
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
• 208000015023 Graves' disease Diseases 0.000 description 3
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
• 102100031004 Histidine-tRNA ligase, cytoplasmic Human genes 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• 208000011200 Kawasaki disease Diseases 0.000 description 3
• 241000186779 Listeria monocytogenes Species 0.000 description 3
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
• 208000029578 Muscle disease Diseases 0.000 description 3
• 102100022437 Myotonin-protein kinase Human genes 0.000 description 3
• 208000030852 Parasitic disease Diseases 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 241000219061 Rheum Species 0.000 description 3
• 201000009594 Systemic Scleroderma Diseases 0.000 description 3
• 206010042953 Systemic sclerosis Diseases 0.000 description 3
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
• 208000024780 Urticaria Diseases 0.000 description 3
• 201000008616 Usher syndrome type 1 Diseases 0.000 description 3
• 201000008554 Usher syndrome type 3A Diseases 0.000 description 3
• 208000012886 Vertigo Diseases 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 206010047924 Wheezing Diseases 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 239000013566 allergen Substances 0.000 description 3
• 210000004102 animal cell Anatomy 0.000 description 3
• 230000003078 antioxidant effect Effects 0.000 description 3
• 206010003119 arrhythmia Diseases 0.000 description 3
• 230000006793 arrhythmia Effects 0.000 description 3
• 230000036760 body temperature Effects 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 210000000845 cartilage Anatomy 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 239000002771 cell marker Substances 0.000 description 3
• 239000002738 chelating agent Substances 0.000 description 3
• 239000003638 chemical reducing agent Substances 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 3
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 230000003292 diminished effect Effects 0.000 description 3
• 210000000883 ear external Anatomy 0.000 description 3
• 229920002549 elastin Polymers 0.000 description 3
• 210000000750 endocrine system Anatomy 0.000 description 3
• 230000007613 environmental effect Effects 0.000 description 3
• 210000000981 epithelium Anatomy 0.000 description 3
• 239000000835 fiber Substances 0.000 description 3
• 210000000232 gallbladder Anatomy 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 230000009395 genetic defect Effects 0.000 description 3
• 210000003714 granulocyte Anatomy 0.000 description 3
• 210000004247 hand Anatomy 0.000 description 3
• 230000009931 harmful effect Effects 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 230000009878 intermolecular interaction Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 239000002085 irritant Substances 0.000 description 3
• 231100000021 irritant Toxicity 0.000 description 3
• 210000002429 large intestine Anatomy 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 230000021633 leukocyte mediated immunity Effects 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 230000001926 lymphatic effect Effects 0.000 description 3
• 210000004324 lymphatic system Anatomy 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• 210000000214 mouth Anatomy 0.000 description 3
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 238000001964 muscle biopsy Methods 0.000 description 3
• 208000013465 muscle pain Diseases 0.000 description 3
• 208000016334 muscle symptom Diseases 0.000 description 3
• 210000002346 musculoskeletal system Anatomy 0.000 description 3
• 206010028417 myasthenia gravis Diseases 0.000 description 3
• 210000004165 myocardium Anatomy 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 230000002956 necrotizing effect Effects 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 230000001717 pathogenic effect Effects 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 208000001297 phlebitis Diseases 0.000 description 3
• 239000008363 phosphate buffer Substances 0.000 description 3
• 229920000136 polysorbate Polymers 0.000 description 3
• 229950008882 polysorbate Drugs 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000002797 proteolythic effect Effects 0.000 description 3
• 201000003004 ptosis Diseases 0.000 description 3
• 210000000664 rectum Anatomy 0.000 description 3
• 230000029058 respiratory gaseous exchange Effects 0.000 description 3
• 210000002345 respiratory system Anatomy 0.000 description 3
• 206010039722 scoliosis Diseases 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 210000002460 smooth muscle Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 210000000278 spinal cord Anatomy 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000010257 thawing Methods 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 238000011285 therapeutic regimen Methods 0.000 description 3
• 201000005060 thrombophlebitis Diseases 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 210000003932 urinary bladder Anatomy 0.000 description 3
• 210000002229 urogenital system Anatomy 0.000 description 3
• 229960005486 vaccine Drugs 0.000 description 3
• 210000005167 vascular cell Anatomy 0.000 description 3
• 239000013598 vector Substances 0.000 description 3
• 231100000889 vertigo Toxicity 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 210000000707 wrist Anatomy 0.000 description 3
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
• 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
• 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 206010067484 Adverse reaction Diseases 0.000 description 2
• 201000000736 Amenorrhea Diseases 0.000 description 2
• 206010001928 Amenorrhoea Diseases 0.000 description 2
• 206010001935 American trypanosomiasis Diseases 0.000 description 2
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
• 206010002198 Anaphylactic reaction Diseases 0.000 description 2
• 108020005098 Anticodon Proteins 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• 208000003017 Aortic Valve Stenosis Diseases 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010003671 Atrioventricular Block Diseases 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 208000010392 Bone Fractures Diseases 0.000 description 2
• 206010006482 Bronchospasm Diseases 0.000 description 2
• 101710116319 CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 206010008027 Cerebellar atrophy Diseases 0.000 description 2
• 208000024699 Chagas disease Diseases 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 201000006082 Chickenpox Diseases 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 208000015943 Coeliac disease Diseases 0.000 description 2
• 208000029147 Collagen-vascular disease Diseases 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• 208000034656 Contusions Diseases 0.000 description 2
• 206010011219 Costochondritis Diseases 0.000 description 2
• 201000007336 Cryptococcosis Diseases 0.000 description 2
• 241000221204 Cryptococcus neoformans Species 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 206010011891 Deafness neurosensory Diseases 0.000 description 2
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 102000016942 Elastin Human genes 0.000 description 2
• 108010014258 Elastin Proteins 0.000 description 2
• 208000005189 Embolism Diseases 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 208000004262 Food Hypersensitivity Diseases 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 208000007465 Giant cell arteritis Diseases 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• 206010018691 Granuloma Diseases 0.000 description 2
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
• 241000606768 Haemophilus influenzae Species 0.000 description 2
• 208000010271 Heart Block Diseases 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
• 206010021263 IgA nephropathy Diseases 0.000 description 2
• 208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
• 208000024781 Immune Complex disease Diseases 0.000 description 2
• 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 206010022489 Insulin Resistance Diseases 0.000 description 2
• 102100037850 Interferon gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
• 208000000209 Isaacs syndrome Diseases 0.000 description 2
• 208000012528 Juvenile dermatomyositis Diseases 0.000 description 2
• 108010093008 Kinins Proteins 0.000 description 2
• 102000002397 Kinins Human genes 0.000 description 2
• 241000588748 Klebsiella Species 0.000 description 2
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
• 102000016267 Leptin Human genes 0.000 description 2
• 108010092277 Leptin Proteins 0.000 description 2
• 241000239218 Limulus Species 0.000 description 2
• 208000016604 Lyme disease Diseases 0.000 description 2
• 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
• 206010028424 Myasthenic syndrome Diseases 0.000 description 2
• 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 2
• 208000023137 Myotoxicity Diseases 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 241000588650 Neisseria meningitidis Species 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 206010029240 Neuritis Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 208000001140 Night Blindness Diseases 0.000 description 2
• 102000005503 Non-Receptor Type 22 Protein Tyrosine Phosphatase Human genes 0.000 description 2
• 108010031988 Non-Receptor Type 22 Protein Tyrosine Phosphatase Proteins 0.000 description 2
• 108091005461 Nucleic proteins Proteins 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 208000027771 Obstructive airways disease Diseases 0.000 description 2
• 206010031149 Osteitis Diseases 0.000 description 2
• 208000005141 Otitis Diseases 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
• 241000223960 Plasmodium falciparum Species 0.000 description 2
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
• 206010036105 Polyneuropathy Diseases 0.000 description 2
• 229920001219 Polysorbate 40 Polymers 0.000 description 2
• 229920001214 Polysorbate 60 Polymers 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• 206010036790 Productive cough Diseases 0.000 description 2
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 208000037656 Respiratory Sounds Diseases 0.000 description 2
• 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 208000035286 Spontaneous Remission Diseases 0.000 description 2
• 241000295644 Staphylococcaceae Species 0.000 description 2
• 241000191940 Staphylococcus Species 0.000 description 2
• 241000193985 Streptococcus agalactiae Species 0.000 description 2
• 241000193998 Streptococcus pneumoniae Species 0.000 description 2
• 208000033809 Suppuration Diseases 0.000 description 2
• 208000018359 Systemic autoimmune disease Diseases 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 208000000491 Tendinopathy Diseases 0.000 description 2
• 206010043255 Tendonitis Diseases 0.000 description 2
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 208000026317 Tietze syndrome Diseases 0.000 description 2
• 241000159243 Toxicodendron radicans Species 0.000 description 2
• 108700009124 Transcription Initiation Site Proteins 0.000 description 2
• 206010045240 Type I hypersensitivity Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 206010046980 Varicella Diseases 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 229960004308 acetylcysteine Drugs 0.000 description 2
• 206010069351 acute lung injury Diseases 0.000 description 2
• 210000004100 adrenal gland Anatomy 0.000 description 2
• 201000010411 adult dermatomyositis Diseases 0.000 description 2
• 230000006838 adverse reaction Effects 0.000 description 2
• 231100000540 amenorrhea Toxicity 0.000 description 2
• 229960005260 amiodarone Drugs 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 230000036783 anaphylactic response Effects 0.000 description 2
• 208000003455 anaphylaxis Diseases 0.000 description 2
• 210000003484 anatomy Anatomy 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 230000010100 anticoagulation Effects 0.000 description 2
• 206010002906 aortic stenosis Diseases 0.000 description 2
• 230000004596 appetite loss Effects 0.000 description 2
• 239000002948 appetite stimulant Substances 0.000 description 2
• 229940029995 appetite stimulants Drugs 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 235000009697 arginine Nutrition 0.000 description 2
• 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 210000003651 basophil Anatomy 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 210000002533 bulbourethral gland Anatomy 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 230000000453 cell autonomous effect Effects 0.000 description 2
• 229960005110 cerivastatin Drugs 0.000 description 2
• SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
• 210000003679 cervix uteri Anatomy 0.000 description 2
• 125000003636 chemical group Chemical group 0.000 description 2
• 230000003399 chemotactic effect Effects 0.000 description 2
• 201000010415 childhood type dermatomyositis Diseases 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 230000009194 climbing Effects 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 208000018631 connective tissue disease Diseases 0.000 description 2
• 238000010924 continuous production Methods 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 230000002354 daily effect Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 229960002086 dextran Drugs 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 235000015872 dietary supplement Nutrition 0.000 description 2
• 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000002845 discoloration Methods 0.000 description 2
• 208000002173 dizziness Diseases 0.000 description 2
• 210000003027 ear inner Anatomy 0.000 description 2
• 210000000959 ear middle Anatomy 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 210000003238 esophagus Anatomy 0.000 description 2
• 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
• 230000008622 extracellular signaling Effects 0.000 description 2
• 208000024711 extrinsic asthma Diseases 0.000 description 2
• 210000000416 exudates and transudate Anatomy 0.000 description 2
• 210000001508 eye Anatomy 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 230000020764 fibrinolysis Effects 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 230000003176 fibrotic effect Effects 0.000 description 2
• 235000020932 food allergy Nutrition 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• 239000003517 fume Substances 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 210000005095 gastrointestinal system Anatomy 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 208000010758 granulomatous inflammation Diseases 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 108010023829 hepatocyte growth factor-regulated tyrosine kinase substrate Proteins 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 210000003016 hypothalamus Anatomy 0.000 description 2
• 208000003532 hypothyroidism Diseases 0.000 description 2
• 230000002989 hypothyroidism Effects 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
• 230000000366 juvenile effect Effects 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 208000019017 loss of appetite Diseases 0.000 description 2
• 235000021266 loss of appetite Nutrition 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 238000005399 mechanical ventilation Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 210000002418 meninge Anatomy 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 238000005065 mining Methods 0.000 description 2
• 230000037230 mobility Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 230000020763 muscle atrophy Effects 0.000 description 2
• 230000003274 myotonic effect Effects 0.000 description 2
• 230000001338 necrotic effect Effects 0.000 description 2
• 201000008383 nephritis Diseases 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
• 210000001331 nose Anatomy 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 230000000414 obstructive effect Effects 0.000 description 2
• 238000002515 oligonucleotide synthesis Methods 0.000 description 2
• 230000010494 opalescence Effects 0.000 description 2
• 210000004789 organ system Anatomy 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 210000003101 oviduct Anatomy 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 210000005259 peripheral blood Anatomy 0.000 description 2
• 239000011886 peripheral blood Substances 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 230000001766 physiological effect Effects 0.000 description 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
• 230000001817 pituitary effect Effects 0.000 description 2
• 239000002574 poison Substances 0.000 description 2
• 231100000614 poison Toxicity 0.000 description 2
• 229920001983 poloxamer Polymers 0.000 description 2
• 229960000502 poloxamer Drugs 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000007824 polyneuropathy Effects 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
• 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
• 229940101027 polysorbate 40 Drugs 0.000 description 2
• 229940113124 polysorbate 60 Drugs 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 201000007094 prostatitis Diseases 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 238000012959 renal replacement therapy Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 201000003068 rheumatic fever Diseases 0.000 description 2
• 230000033764 rhythmic process Effects 0.000 description 2
• 230000000630 rising effect Effects 0.000 description 2
• 201000005404 rubella Diseases 0.000 description 2
• 210000003296 saliva Anatomy 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 230000037390 scarring Effects 0.000 description 2
• 208000008742 seborrheic dermatitis Diseases 0.000 description 2
• 210000001625 seminal vesicle Anatomy 0.000 description 2
• 208000023573 sensorineural hearing loss disease Diseases 0.000 description 2
• 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 2
• 210000002151 serous membrane Anatomy 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 231100000046 skin rash Toxicity 0.000 description 2
• 239000000779 smoke Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000011272 standard treatment Methods 0.000 description 2
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 208000006379 syphilis Diseases 0.000 description 2
• 230000008718 systemic inflammatory response Effects 0.000 description 2
• 206010043207 temporal arteritis Diseases 0.000 description 2
• 201000004415 tendinitis Diseases 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 210000003437 trachea Anatomy 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 230000005951 type IV hypersensitivity Effects 0.000 description 2
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 210000000626 ureter Anatomy 0.000 description 2
• 210000003708 urethra Anatomy 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 230000024883 vasodilation Effects 0.000 description 2
• 201000010653 vesiculitis Diseases 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 210000003905 vulva Anatomy 0.000 description 2
• 208000016261 weight loss Diseases 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
• VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• QWVCIORZLNBIIC-UHFFFAOYSA-N 2,3-dibromopropan-1-ol Chemical compound OCC(Br)CBr QWVCIORZLNBIIC-UHFFFAOYSA-N 0.000 description 1
• SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
• 108700005239 3-Hydroxyacyl-CoA Dehydrogenase Deficiency Proteins 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• XWHHYOYVRVGJJY-UHFFFAOYSA-N 4-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 244000283070 Abies balsamea Species 0.000 description 1
• 235000007173 Abies balsamea Nutrition 0.000 description 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
• 208000010444 Acidosis Diseases 0.000 description 1
• 241000589291 Acinetobacter Species 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• 206010000598 Acrodynia Diseases 0.000 description 1
• 231100000455 Acrodynia Toxicity 0.000 description 1
• 206010000807 Acute HIV infection Diseases 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
• 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 208000002016 Adenosine monophosphate deaminase deficiency Diseases 0.000 description 1
• 102000014777 Adipokines Human genes 0.000 description 1
• 108010078606 Adipokines Proteins 0.000 description 1
• 102000011690 Adiponectin Human genes 0.000 description 1
• 108010076365 Adiponectin Proteins 0.000 description 1
• 206010001367 Adrenal insufficiency Diseases 0.000 description 1
• 208000006888 Agnosia Diseases 0.000 description 1
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
• 108010082126 Alanine transaminase Proteins 0.000 description 1
• 108010058060 Alanine-tRNA ligase Proteins 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 206010027654 Allergic conditions Diseases 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 206010058285 Allergy to arthropod bite Diseases 0.000 description 1
• 108091023043 Alu Element Proteins 0.000 description 1
• 241000224489 Amoeba Species 0.000 description 1
• 206010001981 Amoebic infections Diseases 0.000 description 1
• 102000008873 Angiotensin II receptor Human genes 0.000 description 1
• 108050000824 Angiotensin II receptor Proteins 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 244000106483 Anogeissus latifolia Species 0.000 description 1
• 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 206010003011 Appendicitis Diseases 0.000 description 1
• 206010003062 Apraxia Diseases 0.000 description 1
• 206010003178 Arterial thrombosis Diseases 0.000 description 1
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
• 208000008037 Arthrogryposis Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 206010003557 Asthma exercise induced Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 230000019970 B cell anergy Effects 0.000 description 1
• 241000304886 Bacilli Species 0.000 description 1
• 208000031729 Bacteremia Diseases 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 241000228405 Blastomyces dermatitidis Species 0.000 description 1
• 208000009766 Blau syndrome Diseases 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000589969 Borreliella burgdorferi Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000009079 Bronchial Spasm Diseases 0.000 description 1
• 208000014181 Bronchial disease Diseases 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• 206010006811 Bursitis Diseases 0.000 description 1
• 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
• 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
• 201000003274 CINCA syndrome Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 208000006017 Cardiac Tamponade Diseases 0.000 description 1
• 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
• 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
• 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 206010007882 Cellulitis Diseases 0.000 description 1
• 206010008025 Cerebellar ataxia Diseases 0.000 description 1
• 206010063094 Cerebral malaria Diseases 0.000 description 1
• 241001529572 Chaceon affinis Species 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• 208000009043 Chemical Burns Diseases 0.000 description 1
• 102000000018 Chemokine CCL2 Human genes 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 206010008469 Chest discomfort Diseases 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
• 241000223205 Coccidioides immitis Species 0.000 description 1
• ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
• 206010009895 Colitis ischaemic Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 206010010254 Concussion Diseases 0.000 description 1
• 208000000781 Conductive Hearing Loss Diseases 0.000 description 1
• 206010010280 Conductive deafness Diseases 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 201000007045 Congenital toxoplasmosis Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 208000025962 Crush injury Diseases 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
• 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
• 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 101150054841 DUX4 gene Proteins 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 206010012205 Delayed puberty Diseases 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 206010012441 Dermatitis bullous Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 102100026992 Dermcidin Human genes 0.000 description 1
• 208000001154 Dermoid Cyst Diseases 0.000 description 1
• 206010051392 Diapedesis Diseases 0.000 description 1
• 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
• 206010061819 Disease recurrence Diseases 0.000 description 1
• 208000003870 Drug Overdose Diseases 0.000 description 1
• 206010013654 Drug abuse Diseases 0.000 description 1
• 206010013700 Drug hypersensitivity Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 206010013976 Dyspraxia Diseases 0.000 description 1
• UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
• 101150111184 Emd gene Proteins 0.000 description 1
• 206010014612 Encephalitis viral Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 241000588914 Enterobacter Species 0.000 description 1
• 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
• 208000010305 Epidermal Cyst Diseases 0.000 description 1
• 239000004593 Epoxy Substances 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 206010015226 Erythema nodosum Diseases 0.000 description 1
• 208000030644 Esophageal Motility disease Diseases 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 206010015995 Eyelid ptosis Diseases 0.000 description 1
• 206010051267 Facial paresis Diseases 0.000 description 1
• 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
• 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
• 208000035690 Familial cold urticaria Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 201000006353 Filariasis Diseases 0.000 description 1
• 241000192125 Firmicutes Species 0.000 description 1
• 206010016946 Food allergy Diseases 0.000 description 1
• 206010017076 Fracture Diseases 0.000 description 1
• 229940123457 Free radical scavenger Drugs 0.000 description 1
• 208000001034 Frostbite Diseases 0.000 description 1
• 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
• 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 208000025499 G6PD deficiency Diseases 0.000 description 1
• 208000013135 GNE myopathy Diseases 0.000 description 1
• 206010017711 Gangrene Diseases 0.000 description 1
• 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 description 1
• 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 description 1
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
• 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
• 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 108010068370 Glutens Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010051724 Glycine-tRNA Ligase Proteins 0.000 description 1
• 206010018462 Glycogen storage disease type V Diseases 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000019220 Glycyl-tRNA synthetases Human genes 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 201000005708 Granuloma Annulare Diseases 0.000 description 1
• 239000001922 Gum ghatti Substances 0.000 description 1
• 229920000569 Gum karaya Polymers 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• 108010022901 Heparin Lyase Proteins 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 241000724675 Hepatitis E virus Species 0.000 description 1
• 208000037262 Hepatitis delta Diseases 0.000 description 1
• 241000724709 Hepatitis delta virus Species 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 241000709721 Hepatovirus A Species 0.000 description 1
• 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
• 241000228402 Histoplasma Species 0.000 description 1
• 101000911659 Homo sapiens Dermcidin Proteins 0.000 description 1
• 101001016184 Homo sapiens Dysferlin Proteins 0.000 description 1
• 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
• 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
• 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
• LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000029422 Hypernatremia Diseases 0.000 description 1
• 206010020697 Hyperosmolar state Diseases 0.000 description 1
• 206010020843 Hyperthermia Diseases 0.000 description 1
• 208000004044 Hypesthesia Diseases 0.000 description 1
• 206010048865 Hypoacusis Diseases 0.000 description 1
• 208000013038 Hypocalcemia Diseases 0.000 description 1
• 206010058359 Hypogonadism Diseases 0.000 description 1
• 208000019025 Hypokalemia Diseases 0.000 description 1
• 206010021036 Hyponatraemia Diseases 0.000 description 1
• 208000029663 Hypophosphatemia Diseases 0.000 description 1
• 206010021137 Hypovolaemia Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 241000712431 Influenza A virus Species 0.000 description 1
• 241000713196 Influenza B virus Species 0.000 description 1
• 208000002979 Influenza in Birds Diseases 0.000 description 1
• 206010066966 Inner ear inflammation Diseases 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 102100022338 Integrin alpha-M Human genes 0.000 description 1
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
• 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
• 208000005615 Interstitial Cystitis Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 208000026492 Isaac syndrome Diseases 0.000 description 1
• 206010023025 Ischaemic hepatitis Diseases 0.000 description 1
• 102000029793 Isoleucine-tRNA ligase Human genes 0.000 description 1
• 101710176147 Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
• 206010023129 Jaundice cholestatic Diseases 0.000 description 1
• 206010023204 Joint dislocation Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 206010023379 Ketoacidosis Diseases 0.000 description 1
• 208000007976 Ketosis Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 102100035792 Kininogen-1 Human genes 0.000 description 1
• 102000015335 Ku Autoantigen Human genes 0.000 description 1
• 108010025026 Ku Autoantigen Proteins 0.000 description 1
• 206010023509 Kyphosis Diseases 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
• GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 101150077556 LMNA gene Proteins 0.000 description 1
• 206010023567 Labyrinthitis Diseases 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• 208000007811 Latex Hypersensitivity Diseases 0.000 description 1
• 241000589242 Legionella pneumophila Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
• 208000000185 Localized scleroderma Diseases 0.000 description 1
• 208000032376 Lung infection Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 208000008771 Lymphadenopathy Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 101710091439 Major capsid protein 1 Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
• 206010027253 Meningitis pneumococcal Diseases 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 208000008763 Mercury poisoning Diseases 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 206010027417 Metabolic acidosis Diseases 0.000 description 1
• 206010027439 Metal poisoning Diseases 0.000 description 1
• 206010065838 Middle ear inflammation Diseases 0.000 description 1
• 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
• 206010027982 Morphoea Diseases 0.000 description 1
• 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
• 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 1
• 208000010718 Multiple Organ Failure Diseases 0.000 description 1
• 208000006670 Multiple fractures Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 206010049565 Muscle fatigue Diseases 0.000 description 1
• 206010048654 Muscle fibrosis Diseases 0.000 description 1
• 206010028331 Muscle rupture Diseases 0.000 description 1
• 206010050031 Muscle strain Diseases 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 102100030856 Myoglobin Human genes 0.000 description 1
• 108010062374 Myoglobin Proteins 0.000 description 1
• 206010061533 Myotonia Diseases 0.000 description 1
• 206010028665 Myxoedema Diseases 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 241000224438 Naegleria fowleri Species 0.000 description 1
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
• 241001212279 Neisseriales Species 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 1
• 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 208000031662 Noncommunicable disease Diseases 0.000 description 1
• 101710149086 Nuclease S1 Proteins 0.000 description 1
• 201000005267 Obstructive Jaundice Diseases 0.000 description 1
• 206010073310 Occupational exposures Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000008558 Osteophyte Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 206010033078 Otitis media Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 206010033296 Overdoses Diseases 0.000 description 1
• 208000012094 Overlap myositis Diseases 0.000 description 1
• 201000008470 PAPA syndrome Diseases 0.000 description 1
• 208000016222 Pancreatic disease Diseases 0.000 description 1
• 206010033649 Pancreatitis chronic Diseases 0.000 description 1
• 208000009182 Parasitemia Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 206010034701 Peroneal nerve palsy Diseases 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 241000233872 Pneumocystis carinii Species 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 1
• 206010057244 Post viral fatigue syndrome Diseases 0.000 description 1
• 241000932075 Priacanthus hamrur Species 0.000 description 1
• 208000034943 Primary Sjögren syndrome Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710149031 Probable isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
• 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 206010072222 Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Diseases 0.000 description 1
• 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
• 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 206010063562 Radiation skin injury Diseases 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
• 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 102000018120 Recombinases Human genes 0.000 description 1
• 108010091086 Recombinases Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 102000007156 Resistin Human genes 0.000 description 1
• 108010047909 Resistin Proteins 0.000 description 1
• 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 201000007737 Retinal degeneration Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 206010039251 Rubber sensitivity Diseases 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
• 108010083379 Sarcoglycans Proteins 0.000 description 1
• 102000006308 Sarcoglycans Human genes 0.000 description 1
• 206010048908 Seasonal allergy Diseases 0.000 description 1
• 206010039792 Seborrhoea Diseases 0.000 description 1
• 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
• 208000036623 Severe mental retardation Diseases 0.000 description 1
• 208000019802 Sexually transmitted disease Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 201000001828 Sly syndrome Diseases 0.000 description 1
• 241000589970 Spirochaetales Species 0.000 description 1
• 206010041925 Staphylococcal infections Diseases 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 241000934878 Sterculia Species 0.000 description 1
• 208000003018 Sternocostoclavicular Hyperostosis Diseases 0.000 description 1
• 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 206010061372 Streptococcal infection Diseases 0.000 description 1
• 208000013201 Stress fracture Diseases 0.000 description 1
• 102100030416 Stromelysin-1 Human genes 0.000 description 1
• 241000272534 Struthio camelus Species 0.000 description 1
• 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
• 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
• 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
• 206010042496 Sunburn Diseases 0.000 description 1
• 230000017274 T cell anergy Effects 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010043298 Testicular atrophy Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 206010053615 Thermal burn Diseases 0.000 description 1
• 102000002932 Thiolase Human genes 0.000 description 1
• 108060008225 Thiolase Proteins 0.000 description 1
• 108010029287 Threonine-tRNA ligase Proteins 0.000 description 1
• 102100034997 Threonine-tRNA ligase, mitochondrial Human genes 0.000 description 1
• 208000024799 Thyroid disease Diseases 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
• 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 241000159241 Toxicodendron Species 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 102000003929 Transaminases Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102100035559 Transcriptional activator GLI3 Human genes 0.000 description 1
• 241000589884 Treponema pallidum Species 0.000 description 1
• 102000004903 Troponin Human genes 0.000 description 1
• 108090001027 Troponin Proteins 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 206010054000 Type II hypersensitivity Diseases 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 208000037386 Typhoid Diseases 0.000 description 1
• 102000018165 U1 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
• 108010091281 U1 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
• 206010065584 Urethral stenosis Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 241000700647 Variola virus Species 0.000 description 1
• 208000035868 Vascular inflammations Diseases 0.000 description 1
• OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
• 206010058874 Viraemia Diseases 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 229930003448 Vitamin K Natural products 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 208000010399 Wasting Syndrome Diseases 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• 208000003152 Yellow Fever Diseases 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 238000005299 abrasion Methods 0.000 description 1
• 206010000269 abscess Diseases 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 208000024340 acute graft versus host disease Diseases 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 239000000478 adipokine Substances 0.000 description 1
• 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
• 239000003463 adsorbent Substances 0.000 description 1
• 229960002629 agomelatine Drugs 0.000 description 1
• YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 1
• 238000003915 air pollution Methods 0.000 description 1
• 210000004712 air sac Anatomy 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
• 229960003459 allopurinol Drugs 0.000 description 1
• 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
• UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 210000001691 amnion Anatomy 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 229940124650 anti-cancer therapies Drugs 0.000 description 1
• 230000002583 anti-histone Effects 0.000 description 1
• 230000002924 anti-infective effect Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 229940124604 anti-psychotic medication Drugs 0.000 description 1
• 230000000469 anti-sperm effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 229960005475 antiinfective agent Drugs 0.000 description 1
• 239000003524 antilipemic agent Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 1
• 101150035354 araA gene Proteins 0.000 description 1
• 210000000576 arachnoid Anatomy 0.000 description 1
• 206010003074 arachnoiditis Diseases 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 206010003549 asthenia Diseases 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 201000010788 atrophy of testis Diseases 0.000 description 1
• 208000001974 autoimmune enteropathy Diseases 0.000 description 1
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
• 201000004339 autoimmune neuropathy Diseases 0.000 description 1
• 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
• 206010064097 avian influenza Diseases 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• 230000036621 balding Effects 0.000 description 1
• 238000009412 basement excavation Methods 0.000 description 1
• 229940088007 benadryl Drugs 0.000 description 1
• 150000004054 benzoquinones Chemical class 0.000 description 1
• 229940124748 beta 2 agonist Drugs 0.000 description 1
• 125000003164 beta-aspartyl group Chemical group 0.000 description 1
• 230000002457 bidirectional effect Effects 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008236 biological pathway Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 239000003114 blood coagulation factor Substances 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 230000008081 blood perfusion Effects 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• 229910052793 cadmium Inorganic materials 0.000 description 1
• BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 101150062912 cct3 gene Proteins 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000013116 chronic cough Diseases 0.000 description 1
• 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
• 208000016532 chronic granulomatous disease Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 229960002173 citrulline Drugs 0.000 description 1
• 235000013477 citrulline Nutrition 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 239000003245 coal Substances 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 210000000860 cochlear nerve Anatomy 0.000 description 1
• 235000017471 coenzyme Q10 Nutrition 0.000 description 1
• 229940110767 coenzyme Q10 Drugs 0.000 description 1
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
• 208000008609 collagenous colitis Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 206010010121 compartment syndrome Diseases 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 230000009514 concussion Effects 0.000 description 1
• 208000023563 conductive hearing loss disease Diseases 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 238000012885 constant function Methods 0.000 description 1
• 238000009563 continuous hemofiltration Methods 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 208000026758 coronary atherosclerosis Diseases 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 210000003674 cytoplasmic vesicle Anatomy 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 231100000895 deafness Toxicity 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 238000011082 depyrogenation Methods 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 210000004207 dermis Anatomy 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 238000012631 diagnostic technique Methods 0.000 description 1
• 229960002069 diamorphine Drugs 0.000 description 1
• 239000012954 diazonium Substances 0.000 description 1
• 238000003748 differential diagnosis Methods 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 201000008243 diversion colitis Diseases 0.000 description 1
• AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 201000005311 drug allergy Diseases 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 231100000725 drug overdose Toxicity 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 201000011191 dyskinesia of esophagus Diseases 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 208000019258 ear infection Diseases 0.000 description 1
• UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 150000002066 eicosanoids Chemical class 0.000 description 1
• JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
• 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
• 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
• 210000004177 elastic tissue Anatomy 0.000 description 1
• 210000001513 elbow Anatomy 0.000 description 1
• 238000002567 electromyography Methods 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 208000010227 enterocolitis Diseases 0.000 description 1
• 208000019434 enterovirus antenatal infection Diseases 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 208000017338 epidermoid cysts Diseases 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 229950005470 eteplirsen Drugs 0.000 description 1
• HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical group OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 210000003722 extracellular fluid Anatomy 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 210000000744 eyelid Anatomy 0.000 description 1
• 208000010770 facial weakness Diseases 0.000 description 1
• 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 description 1
• 210000001752 female genitalia Anatomy 0.000 description 1
• 229940125753 fibrate Drugs 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 235000021323 fish oil Nutrition 0.000 description 1
• 238000002637 fluid replacement therapy Methods 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 208000020694 gallbladder disease Diseases 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 229960003627 gemfibrozil Drugs 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000004554 glutamine Nutrition 0.000 description 1
• 229960000587 glutaral Drugs 0.000 description 1
• 235000021312 gluten Nutrition 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 208000007345 glycogen storage disease Diseases 0.000 description 1
• 201000004534 glycogen storage disease V Diseases 0.000 description 1
• 201000009339 glycogen storage disease VII Diseases 0.000 description 1
• 230000004116 glycogenolysis Effects 0.000 description 1
• 230000034659 glycolysis Effects 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 210000002149 gonad Anatomy 0.000 description 1
• 230000036449 good health Effects 0.000 description 1
• 235000015201 grapefruit juice Nutrition 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 238000001631 haemodialysis Methods 0.000 description 1
• 229940047650 haemophilus influenzae Drugs 0.000 description 1
• 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 208000006750 hematuria Diseases 0.000 description 1
• 230000000322 hemodialysis Effects 0.000 description 1
• 238000002615 hemofiltration Methods 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 208000002557 hidradenitis Diseases 0.000 description 1
• 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
• 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 239000004030 hiv protease inhibitor Substances 0.000 description 1
• 239000012510 hollow fiber Substances 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 230000009097 homeostatic mechanism Effects 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 239000012456 homogeneous solution Substances 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000056610 human DYSF Human genes 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 150000002429 hydrazines Chemical class 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 230000003345 hyperglycaemic effect Effects 0.000 description 1
• 230000035874 hyperreactivity Effects 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 230000036031 hyperthermia Effects 0.000 description 1
• 230000000705 hypocalcaemia Effects 0.000 description 1
• 230000002631 hypothermal effect Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 230000005931 immune cell recruitment Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000003832 immune regulation Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003318 immunodepletion Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 201000006747 infectious mononucleosis Diseases 0.000 description 1
• 230000001524 infective effect Effects 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 239000002919 insect venom Substances 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 201000006334 interstitial nephritis Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 229940008228 intravenous immunoglobulins Drugs 0.000 description 1
• 230000010438 iron metabolism Effects 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 208000001875 irritant dermatitis Diseases 0.000 description 1
• 230000000622 irritating effect Effects 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 201000008222 ischemic colitis Diseases 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
• 229960003350 isoniazid Drugs 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• 208000018937 joint inflammation Diseases 0.000 description 1
• 235000010494 karaya gum Nutrition 0.000 description 1
• 239000000231 karaya gum Substances 0.000 description 1
• 229940039371 karaya gum Drugs 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 229960004125 ketoconazole Drugs 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 208000026585 laminopathy Diseases 0.000 description 1
• 201000005391 latex allergy Diseases 0.000 description 1
• 229940115932 legionella pneumophila Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• 235000005772 leucine Nutrition 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 208000006132 lipodystrophy Diseases 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000018191 liver inflammation Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
• 229960003088 loratadine Drugs 0.000 description 1
• 208000020442 loss of weight Diseases 0.000 description 1
• 230000004777 loss-of-function mutation Effects 0.000 description 1
• 208000030208 low-grade fever Diseases 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000005004 lymphoid follicle Anatomy 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 230000034217 membrane fusion Effects 0.000 description 1
• 230000008172 membrane trafficking Effects 0.000 description 1
• 210000005033 mesothelial cell Anatomy 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 206010063344 microscopic polyangiitis Diseases 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
• 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 230000003843 mucus production Effects 0.000 description 1
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
• 208000037890 multiple organ injury Diseases 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• 206010028320 muscle necrosis Diseases 0.000 description 1
• 208000015004 muscle tenderness Diseases 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 239000002636 mycotoxin Substances 0.000 description 1
• 208000003786 myxedema Diseases 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 229960001800 nefazodone Drugs 0.000 description 1
• VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
• 210000001640 nerve ending Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 239000000842 neuromuscular blocking agent Substances 0.000 description 1
• 201000009985 neuronitis Diseases 0.000 description 1
• 208000000288 neurosarcoidosis Diseases 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
• 229960001597 nifedipine Drugs 0.000 description 1
• NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
• 229960000564 nitrofurantoin Drugs 0.000 description 1
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 210000000633 nuclear envelope Anatomy 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• 208000007892 occupational asthma Diseases 0.000 description 1
• 150000002482 oligosaccharides Polymers 0.000 description 1
• 229960000381 omeprazole Drugs 0.000 description 1
• SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 201000005261 otitis interna Diseases 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 239000011236 particulate material Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 238000012510 peptide mapping method Methods 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 230000005043 peripheral vision Effects 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 238000000554 physical therapy Methods 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 208000004593 pneumococcal meningitis Diseases 0.000 description 1
• 201000004338 pollen allergy Diseases 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 210000004896 polypeptide structure Anatomy 0.000 description 1
• 208000024896 potassium deficiency disease Diseases 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 208000037920 primary disease Diseases 0.000 description 1
• 239000012602 primary packaging material Substances 0.000 description 1
• 230000002947 procoagulating effect Effects 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 208000026526 progressive weakness Diseases 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 206010036934 prostatic abscess Diseases 0.000 description 1
• 229940048914 protamine Drugs 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 208000028172 protozoa infectious disease Diseases 0.000 description 1
• 210000003456 pulmonary alveoli Anatomy 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
• 208000022638 pyogenic arthritis-pyoderma gangrenosum-acne syndrome Diseases 0.000 description 1
• 229960005206 pyrazinamide Drugs 0.000 description 1
• IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000002040 relaxant effect Effects 0.000 description 1
• 206010038351 renal abscess Diseases 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000036387 respiratory rate Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000004258 retinal degeneration Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 229960001225 rifampicin Drugs 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 210000002235 sarcomere Anatomy 0.000 description 1
• 208000001076 sarcopenia Diseases 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 208000037921 secondary disease Diseases 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 239000011669 selenium Substances 0.000 description 1
• 235000011649 selenium Nutrition 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
• 210000004911 serous fluid Anatomy 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 230000022379 skeletal muscle tissue development Effects 0.000 description 1
• 238000007390 skin biopsy Methods 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 201000008261 skin carcinoma Diseases 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000003998 snake venom Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229960001790 sodium citrate Drugs 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 230000007103 stamina Effects 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000009168 stem cell therapy Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 210000002330 subarachnoid space Anatomy 0.000 description 1
• 230000004960 subcellular localization Effects 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000008409 synovial inflammation Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 229920005613 synthetic organic polymer Polymers 0.000 description 1
• 208000008203 tachypnea Diseases 0.000 description 1
• 206010043089 tachypnoea Diseases 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 231100001044 testicular atrophy Toxicity 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• YTQVHRVITVLIRD-UHFFFAOYSA-L thallium sulfate Chemical compound [Tl+].[Tl+].[O-]S([O-])(=O)=O YTQVHRVITVLIRD-UHFFFAOYSA-L 0.000 description 1
• 229940119523 thallium sulfate Drugs 0.000 description 1
• 229910000374 thallium(I) sulfate Inorganic materials 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 230000036575 thermal burns Effects 0.000 description 1
• 230000010512 thermal transition Effects 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 201000006395 thrombophlebitis migrans Diseases 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 208000021510 thyroid gland disease Diseases 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• 125000005490 tosylate group Chemical group 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003918 triazines Chemical class 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 201000002311 trypanosomiasis Diseases 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 230000009959 type I hypersensitivity Effects 0.000 description 1
• 230000008026 type II hypersensitivity Effects 0.000 description 1
• 230000028063 type III hypersensitivity Effects 0.000 description 1
• 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
• 201000008297 typhoid fever Diseases 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 201000001988 urethral stricture Diseases 0.000 description 1
• 208000000143 urethritis Diseases 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 208000019206 urinary tract infection Diseases 0.000 description 1
• 210000003934 vacuole Anatomy 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 208000034280 venom allergy Diseases 0.000 description 1
• 210000003273 vestibular nerve Anatomy 0.000 description 1
• 201000000200 vestibular neuronitis Diseases 0.000 description 1
• 201000002498 viral encephalitis Diseases 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 235000019168 vitamin K Nutrition 0.000 description 1
• 239000011712 vitamin K Substances 0.000 description 1
• 150000003721 vitamin K derivatives Chemical class 0.000 description 1
• 229940046010 vitamin k Drugs 0.000 description 1
• 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 238000003466 welding Methods 0.000 description 1
• 229960002555 zidovudine Drugs 0.000 description 1
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1